{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/prov/492883726"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/386291309" ] } },

    { "id" : "http://webisa.webdatacommons.org/386291309"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Additionally, PaxVax is acquiring marketing, sales and distribution capabilities in select markets including the United States, and certain other assets related to travel vaccines such as hepatitis A. Financial terms of the transaction were not disclosed. ???Typhoid is one of the most commonly delivered travel vaccines, and this strategic transaction establishes PaxVax as an important supplier glo" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "financialmirror.com" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/424830769"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/386291309"] } } }
